Clinical experience with anti-EGFR therapy

Semin Oncol Nurs. 2006 Feb;22(1 Suppl 1):10-9. doi: 10.1016/j.soncn.2006.01.011.


Objectives: To review clinical experience and studies with anti-EGFR therapies in metastatic CRC, SCCHN, and NSCLC. Case studies in each tumor type will also be outlined.

Data sources: Research articles and patient case histories.

Conclusion: Several phase II/III trials have shown the activity of anti-EGFR therapy in CRC, SCCHN, and NSCLC. Treatment confers substantial clinical benefit with improved symptoms, particularly in previously treated patients. Toxicity of anti-EGFR therapies is generally manageable and non-overlapping with other treatment options, including chemotherapy and radiotherapy.

Implications for nursing practice: It is important for nurses to further advance our understanding of anti-EGFR therapies and continue to encourage patient enrollment in ongoing trials of anti-EGFR therapy.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Carcinoma, Squamous Cell / drug therapy
  • Cetuximab
  • Colorectal Neoplasms / drug therapy
  • ErbB Receptors / antagonists & inhibitors*
  • Erlotinib Hydrochloride
  • Fatal Outcome
  • Female
  • Gefitinib
  • Head and Neck Neoplasms / drug therapy
  • Humans
  • Lung Neoplasms / drug therapy
  • Male
  • Neoplasms / drug therapy*
  • Neoplasms / mortality
  • Quinazolines / therapeutic use
  • Radiotherapy, Adjuvant
  • Safety
  • Survival Rate
  • Treatment Outcome


  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Quinazolines
  • Erlotinib Hydrochloride
  • ErbB Receptors
  • Cetuximab
  • Gefitinib